tweenvest

Vigonvita Life Sciences Co., Ltd. (SEHK: 2630)

Health Care · Pharmaceuticals · CN

HK$72.65

-3.13% today · +7.7% 1Y

Public summary
A free snapshot of Vigonvita Life Sciences Co., Ltd., with figures as of Nov 15, 2026. The full analysis is in the app.Open in the app

Vigonvita Life Sciences Co., Ltd. (SEHK: 2630) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.55B and employs 315 people.

Over the last twelve months the share price has gained 7.7%, trading between 52.00 and 134.90.

Tweenvest scores Vigonvita Life Sciences Co., Ltd. across four factors: quality 31/100, value 49/100. Its strongest factor is value.

2630 price history

Nov 21, 2025 · 60.00Weekly closes 54.00 – 126.00Nov 13, 2026 · 72.65

Key figures

Market cap
$1.55B
Revenue (TTM)
$31.98M
P/E
-31.36
EPS
-2.59
Dividend yield
—
Beta (5Y)
—
52-week high
HK$134.90
52-week low
HK$52.00
Avg volume (3M)
—
Shares outstanding
167.60M
Employees
315
Next earnings
—

About Vigonvita Life Sciences Co., Ltd.

Vigonvita Life Sciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for neuropsychiatry, reproductive health, and viral infection therapeutic areas. Its products include LV232, a first-in-class dual-target 5-HTT/5-HT modulators, which is in Phase II of clinical trial for the treatment of depressive disorder; and TPN171, a type-5 phosphodiesterase inhibitor completed Phase III clinical trial for the treatment of erectile dysfunction. The company also develops VV116, a RNA-dependent RNA polymerase inhibitor completed a Phase II clinical trial for the treatment of respiratory syncytial virus infection, as well as COVID-19 infections; TPN102, a novel antiepileptic drug, which is in Phase I clinical trial for the treatment of epilepsy; VV119, a multi-target serotonin-dopamine activity modulator, which is in Phase I clinical trial for the treatment of psychiatric disorders and schizophrenia; VV261, a novel nucleoside prodrug, which is in Phase I clinical trial for chikungunya, coronaviruses, influenza, and arena virus. In addition, it develops VV913, a novel investigational drug candidate for premature ejaculation; VV147 for the treatment of major depressive disorder; and VV207 for the treatment of adenovirus infection. The company was incorporated in 2013 and is headquartered in Suzhou, China.

ISIN
CNE1000076N3
Founded
2013
Listed since
Nov 6, 2025
Exchange
The Stock Exchange of Hong Kong Ltd.
Currency
HKD
CompanyMarket capPriceDay
Tibet Cheezheng Tibetan Medicine Co., Ltd.SZSE: 002287$1.60BCN¥18.79+0.54%
Braveheart Bio, Inc.NasdaqGM: BRVE$1.59B$19.49-0.66%
Zhejiang CONBA Pharmaceutical Co.,Ltd.SHSE: 600572$1.57BCN¥4.12-0.48%
Fujian Haixi Pharmaceuticals Co., Ltd.SEHK: 2637$1.57BHK$156.00-0.32%
Marksans Pharma LimitedNSEI: MARKSANS$1.53BRs318.50-0.47%
PharmaBlock Sciences (Nanjing), Inc.SZSE: 300725$1.51BCN¥43.40-5.28%
ANI Pharmaceuticals, Inc.NasdaqGM: ANIP$1.51B$71.47+2.11%
Xiamen Kingdomway Group CompanySZSE: 002626$1.51BCN¥16.94+0.89%

Browse every Pharmaceuticals company →